SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly. Eur J Cancer. 1997; 33: 23132314.
  • 2
    Havlik RJ, Yancik R, Long S, Ries L, Edwards B. The National Cancer Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer. 1994; 74(7 Suppl ): 21012106.
  • 3
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin. 2003; 53: 526.
  • 4
    Silverberg E, Lubera JA. Cancer statistics 1988. CA Cancer J Clin. 1988; 38: 522.
  • 5
    Balducci L. Geriatric oncology: challenge for the new century. Eur J Cancer. 2000; 36: 17411754.
  • 6
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311: 899909.
  • 7
    Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coeberg JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998; 21: 105113.
  • 8
    Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000; 117: 12391246.
  • 9
    Raby B, Pater J, Mackillop W. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol. 1995; 13: 19041911.
  • 10
    Crook A, Duffy A, Girling DJ, Souhami RL, Parmar MK. Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Eur Respir J. 1997; 10: 15521558.
  • 11
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21: 22372246.
  • 12
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 21492158.
  • 13
    Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001; 19: 10641070.
  • 14
    Kubota K, Furuse K, Kawahara M, et al. Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 1997; 40: 469474.
  • 15
    Souquet PJ, Bombaron P, Brunel-Crova J, Bernard JP. Treatment of advanced and disseminated non small cell lung cancer (NSCLC) in elderly patients: results of MIC regimen[abstract]. Lung Cancer. 1997; 18 (Suppl 1): 24.
  • 16
    Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 173181.
  • 17
    Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger pts (< 70) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 639.
  • 18
    Kelly K, Giarritta S, Hayes S, et al. Should older patients receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308 [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 329a.
  • 19
    Belani CP, Fossella FV. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients[abstract]. Lung Cancer. 2003; 41 (Suppl 2): S18.
  • 20
    Lilenbaum RC, Herndon J, List M, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 1a.
  • 21
    Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003; 98: 779788.
  • 22
    Perrone F, Gallo C, Gridelli C. Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002; 94: 10291031.
  • 23
    Berardi R, Porfiri E, Scarrozzi M, et al. A Phase II study of weekly gemcitabine and cisplatin in elderly patients with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 218b.
  • 24
    Madronal C, Feliu J, Martin G, Phase II trial of low-dose cisplatin and gemcitabine in elderly patients with advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 221b.
  • 25
    Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 30253034.
  • 26
    Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975. J Clin Oncol. 2003; 21: 39093917.
  • 27
    Green M. Lung cancer: small cell and non-small cell. In: JohnsonDH, editor. American Society of Clinical Oncology 2001 Annual Meeting summaries. Alexandria, VA: ASCO Publications, 2001: 6870.
  • 28
    Fidias P, Supko JG, Martins R, et al. A Phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001; 7: 39423949.
  • 29
    Hainsworth JD, Burris HA III, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II trial. Cancer. 2000; 89: 328333.
  • 30
    Gridelli C, Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 2001; 31: 277284.
  • 31
    Gridelli C, Perrone F, Gallo C, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage Phase II study. Eur J Cancer. 1997; 33: 392397.
  • 32
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91: 6672.
  • 33
    Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J Natl Cancer Inst. 2003; 95: 362372.
  • 34
    Herbst RS, Bunn PA. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003; 9: 58135824.
  • 35
    Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7: 29582970.
  • 36
    Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003; 95: 851867.
  • 37
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21: 27872799.
  • 38
    Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist. 2003; 8: 303306.
  • 39
    Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 2003; 21: 26582663.
  • 40
    Pallis AG, Mavroudis D, Androulakis N, et al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Lung Cancer. 2003; 40: 301307.
  • 41
    Copin M, Kommareddy A, Behnken D, et al. Gefitinib in elderly patients with non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 758.
  • 42
    Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small cell lung cancer. Br J Cancer. 2003; 89: 18271829.
  • 43
    Soto Parra H, Cavina R, Zucali P, et al. Gefitinib in elderly patients with progressive, pretreated, non-small cell lung cancer: results from the Istituto Clinico Humanitas. Br J Cancer. 2003; 89 (Suppl 2): S25S35.
  • 44
    Stahel R, Rossi A, Petruzelka L, et al. Lessons from the “Iressa” Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. Br J Cancer. 2003; 89 (Suppl 2): S19S23.
  • 45
    Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer. 2004; 90: 8286.
  • 46
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 21292139.
  • 47
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 14971500.
  • 48
    Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial—INTACT 1. J Clin Oncol. 2004; 22: 777784.
  • 49
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial—INTACT 2. J Clin Oncol. 2004; 22: 785794.
  • 50
    Scagliotti G, Rossi A, Novello S, et al. Gefitinib (ZD 1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 633.
  • 51
    Perez-Soler R, Chachoua A, Huberman M, et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2001; 21: 310a.
  • 52
    Miller VA, Patel J, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a Phase II trial [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 619.
  • 53
    Shepherd FA, Pereira J, Ciuleanu E, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 7022.
  • 54
    Johnson BE, Lucca J, Rabin MS, et al. Preliminary results from a Phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 633.
  • 55
    Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 617.
  • 56
    Herbst RS, Prager D, Hermann R, et al. TRIBUTE—a Phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 617.
  • 57
    Falcey J, Pfister D, Cohen R, et al. A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients with head and neck or lung carcinomas [abstract]. Proc Am Soc Clin Oncol. 1997; 16: 383a.
  • 58
    Kelly K, Hanna N, Rosemberg A, Bunn PA, Needle MN. A multi-centered Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 644.
  • 59
    Robert F, Blumenschein G, Dicke K, Tseng J, Saleh MN, Needle M. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 643.
  • 60
    Kim ES, Mauer AM, Tran HT, et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 642.
  • 61
    Ferrera N. Vascular endothelial growth factor. Trends Cardiovasc Med. 1993; 3: 244250.
  • 62
    Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 1996; 56: 16151620.
  • 63
    Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57: 45934599.
  • 64
    DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized Phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage IIIB/IV NSCLC [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 485a.
  • 65
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22: 21842191.
  • 66
    Eastern Cooperative Oncology Group. Phase II/III randomized study of paclitaxel and carboplatin with or without bevacizumab in patients with advanced, metastatic, or recurrent non-squamous cell non-small cell lung cancer [monograph online]. Available from URL: http://cancer.gov/search/viewclinicaltrials.aspx?version=healthprofessional&cdrid=68744&protocolsearchid=162449 [accessed Nov 20, 2001].
  • 67
    Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002; 62: 46464655.
  • 68
    Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003; 9: 15461556.
  • 69
    Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002; 62: 72847290.
  • 70
    Basser R, Hurwitz H, Barge A, et al. Phase I pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 100a.
  • 71
    Soslow RA, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000; 89: 26372645.
  • 72
    DuBois RN, Smalley WE. Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol. 1996; 31: 898906.
  • 73
    Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci. 2000; 30: 321.
  • 74
    Kelley DJ, Mestre JR, Subbaramaiah K, et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 1997; 18: 795799.
  • 75
    Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 2000; 6: 20062011.
  • 76
    Pyo H, Choy H, Amorino GP, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res. 2001; 7: 29983005.
  • 77
    Johnson DH, Csiki I, Gonzalez A, et al. Cyclooxygenase-2 (COX-2) inhibition in non-small cell lung cancer (NSCLC): preliminary results of a Phase II trial [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 640.
  • 78
    Gadgeel SM, Thatai L, Kraut M, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 684.
  • 79
    Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003; 21: 26452650.
  • 80
    Chaplen RA, Kalemkerian GP, Wozniak A, et al. Celecoxib and weekly docetaxel in elderly or PS 2 patients with advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 638.
  • 81
    Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996; 97: 806813.
  • 82
    Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis. 1998; 19: 13931400.
  • 83
    Ciardiello F, Caputo R, Bianco R, et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase antisense oligonucleotide. J Natl Cancer Inst. 1998; 90: 10871094.
  • 84
    Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2002; 6: 37393747.
  • 85
    Normanno N, Campiglio M, De Luca A, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol. 2002; 13: 6572.
  • 86
    Sandler AB, Blumenschein GR, Henderson T, et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 2004; 23: 127.